Technologies

Currently available antidepressant drugs treat only 70% of persons diagnosed with depressive illness.These drugs show a profile of blocking reuptake of serotonin and norepinephrine.Several lines of evidence, including the NIH STAR*D study suggest that addition of a dopamine reuptake-blocking action could treat refractory depressed individuals.In addition, it is hypothesized that addition of dopamine reuptake blocking action could lead to a faster onset of drug action.This invention comprises several novel chemical entities that potently inhibit reuptake of all three neurotransmitters (serotonin, norepinephrine, and dopamine).